EQRx Inc. (EQRXW)
0.05
0.00 (9.89%)
At close: Jan 16, 2025, 9:00 PM
9.89% (1D)
| Bid | n/a |
| Market Cap | 1.14B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -83.79M |
| EPS (ttm) | -7.653 |
| PE Ratio (ttm) | -0.005945380896380505 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 16,500 |
| Avg. Volume (20D) | 16,500 |
| Open | 0.04 |
| Previous Close | 0.05 |
| Day's Range | 0.04 - 0.06 |
| 52-Week Range | 0.04 - 0.06 |
| Beta | 0.00 |
About EQRXW
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. Its product pipeline in development includes Aumolertinib, an EGFR inhibitor for the treatment of ?EGFR-mutated? non-small cell lung cancer (NSCLC); Sugemalimab, an anti-PD-L1 antibody for the treatment of ?stage III and IV ?NSCLC; Lerociclib, a CDK4/6 inhibitor to treat HR+/HER2- bre...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 20, 2021
Employees 216
Stock Exchange NASDAQ
Ticker Symbol EQRXW
Website https://www.eqrx.com